Atypical antipsychotic approved for acute bipolar mania This atypical antipsychotic is believed to exert its effect through a combination of partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors. An expanded indication for aripiprazole was approved on September 29, 2004, to include the treatment of acute manic and mixed episodes associated with Bipolar Disorder.
FDA Approves Combination Therapy for Pulmonary Arterial Hypertension
March 25th 2024J&J’s Opsynvi is single-tablet combination of macitentan, an endothelin receptor antagonist, and tadalafil, a PDE5 inhibitor. It will be priced on parity with Opsumit, which is also a J&J product to treat patients with PAH.